European institutions and European Union (EU) Member States need to ensure that prostate cancer patients throughout Europe have fast, equitable access to innovative treatments, the European Urology Association (EAU) says in a new White Paper.
The document – Prostate cancer: Recommendations to lower the risk and mortality rate of the most frequent cancer in men – was launched at the seventh Prostate Cancer Europe Roundtable held in Brussels earlier this week.
Among the key recommendations included in the report are:
- High-quality, standardised, integrated care with a focus on a patient-centred multidisciplinary approach.
- Fast, equitable access to innovative treatments and personalised medicines.
- Sustained awareness campaigns.
- Equitable access to novel technological tools.
- Prompt and consistent Health Technology Assessments to guide allocation of resources.
- Implementation of survivorship plans.
With 417,000 new prostate cancer diagnoses and 92,000 deaths per year in Europe, EAU Adjunct Secretary General for Education Prof. Hein Van Poppel stressed the importance of keeping awareness high in the public agenda. “We need the help of the EU to make people aware of prostate cancer and its risks. As one of the cancers with significant mortality rates in Europe, there is a need to focus on specific awareness programmes,” he said.